I found the field of Chemistry very interesting. Saw the article Structure-Based Design of Dimeric Bisbenzimidazole Inhibitors to an Emergent Trimethoprim-Resistant Type II Dihydrofolate Reductase Guides the Design of Monomeric Analogues published in 2019.0. Safety of 3-Hydroxybenzaldehyde, Reprint Addresses Pelletier, JN (corresponding author), Univ Montreal, Dept Biochim, Montreal, PQ H3C 3J7, Canada.; Pelletier, JN (corresponding author), Univ Montreal, Dept Chim, Montreal, PQ H3C 3J7, Canada.; Pelletier, JN (corresponding author), PROTEO, Quebec Network Res Prot Funct Engn & Applicat, Quebec City, PQ G1V 0A6, Canada.; Pelletier, JN (corresponding author), CGCC, Montreal, PQ H3A 0B8, Canada.. The CAS is 100-83-4. Through research, I have a further understanding and discovery of 3-Hydroxybenzaldehyde
The worldwide use of the broad-spectrum antimicrobial trimethoprim (TMP) has induced the rise of TMP-resistant microorganisms. In addition to resistance-causing mutations of the microbial chromosomal dihydrofolate reductase (Dfr), the evolutionarily and structurally unrelated type II Dfrs (DfrBs) have been identified in TMP-resistant microorganisms. DfrBs are intrinsically TMP-resistant and allow bacterial proliferation when the microbial chromosomal Dfr is TMP-inhibited, making these enzymes important targets for inhibitor development. Furthermore, DfrBs occur in multiresistance plasmids, potentially accelerating their dissemination. We previously reported symmetrical bisbenzimidazoles that are the first selective inhibitors of the only well-characterized DfrB, DfrB1. Here, their diversification provides a new series of inhibitors (K-i = 1.7-12.0 mu M). Our results reveal two prominent features: terminal carboxylates and inhibitor length allow the establishment of essential interactions with DfrB1. Two crystal structures demonstrate the simultaneous binding of two inhibitor molecules in the symmetrical active site. Observations of those dimeric inhibitors inspired the design of monomeric analogues, binding in a single copy yet offering similar inhibition potency (K-i = 1.1 and 7.4 mu M). Inhibition of a second member of the DfrB family, DfrB4, suggests the generality of these inhibitors. These results provide key insights into inhibition of the highly TMP-resistant DfrBs, opening avenues to downstream development of antibiotics for combatting this emergent source of resistance.
About 3-Hydroxybenzaldehyde, If you have any questions, you can contact Toulouse, JL; Yachnin, BJ; Ruediger, EH; Deon, D; Gagnon, M; Saint-Jacques, K; Ebert, MCCJC; Forge, D; Bastien, D; Colin, DY; Eynde, JJV; Marinier, A; Berghuis, AM; Pelletier, JN or concate me.. Safety of 3-Hydroxybenzaldehyde
Reference:
Indole alkaloid derivatives as building blocks of natural products from Bacillus thuringiensis and Bacillus velezensis and their antibacterial and antifungal activity study,
,Preparation of Indole Containing Building Blocks for the Regiospecific Construction of Indole Appended Pyrazoles and Pyrroles